What is UNIVIE’s main focus? The main focus of our work comprise the molecular basis of the interaction of ligands with transmembrane transport proteins and prediction of toxicity. For this we combine methods from ligand- and structure-based design with data science and machine learning. How has participating in TransQST impacted your company? We were able […]Read moreMore Tag
From left to right: Barbara Füzi, Gerhard Ecker, Melanie Grandits.
Synapse Research Management Partners
From left to right: Inari Soininen and Mery Loor.
What is SYNAPSE’s main field of specialization? Synapse is a firm specialized in the high-quality management of complex research and development projects in the biomedical sector. In fact, we have close to 15 years of experience preparing and managing research projects in the healthcare sector funded by European programs such as IMI, H2020 or the […]Read moreMore Tag
Eli Lilly and Company Ltd (Eli-Lilly)
Derek Leishman, Senior Research Fellow at Eli Lilly.
What is Eli-Lilly´s main field of specialization? Lilly is a large pharmaceutical company focused on human medicinal products. We are active in most therapeutic areas. How has your company been involved in the project? Lilly has been directly involved in the organ work packages, especially cardiovascular, liver and GI. We have been EFPIA leads in […]Read moreMore Tag
UM (Universiteit Maastricht)
From left to right: Theo de Kok, Daniela Rodriguez, Danyel Jennen.
What is UM’s main focus? At the department of Toxicogenomics of Maastricht University (UM) we have a multidisciplinary team of (cell) biologists, chemists, geneticists, toxicologists and bioinformaticians that is working in close collaboration to establish the biological impact of exposures to potentially toxic compounds and to develop safe therapeutic strategies for genetic and non-genetic diseases. […]Read moreMore Tag
IRIS (Institut de Recherches Internationales Servier)
Image from left to right: Stéphanie Billiald and Sylvain Fouliard.
Contributors: Sylvain Fouliard Stéphanie Billiald Nicolas Sajot What are your main research interests? Within Translational Medicine, the non-Clinical Safety and the Quantitative Pharmacology groups aim at supporting the development of new medications and treatment modalities to improve patients’ lives. Our mission in Translational Medicine is to effectively bridge discovery, preclinical and clinical phases thereby improving […]Read moreMore Tag
The IFADO team.
What is IFADO’s main focus? Our passion is liver physiology, hepatotoxicity and functional imaging. How has participating in TransQST impacted your company? We had the chance to find partners with common interests and complementary technologies; this allowed us to establish exciting collaborations. What challenges has IFADO faced across the project? What are your main achievements […]Read moreMore Tag
UOXF (The Chancellor, Masters and Scholars of the University of Oxford)
Image from left to right: Elisa Passini, Cristian Trovato, Blanca Rodriguez.
What is UOXF´s main focus? We are the Computational Cardiovascular Science Team, based at the Department of Computer Science of the University of Oxford (UK). Our expertise is in human-based computational modelling and simulation for in silico trials and cardiovascular research, to integrate and expand the information extracted from a range of experimental and clinical […]Read moreMore Tag
AZ (AstraZeneca AB)
Image from left to right: (Top row) Amy Pointon, Aydar Uatay, Carmen Pin, Clay Scott, (Middle row) Dominic Williams, Holly Kimko, Jacopo Biasetti, Kenneth Pryde, (Bottow row) Louis Gall, Meghan Verma, Oladipupo Adayemi, Teresa Collins.
What is AZ’s main focus? The academia-industry hybrid environment in TransQST enabled AZ, together with other consortium members, to develop novel mathematical and biological modelling solutions that maximize study subject’s safety during drug development. In particular, we were interested in optimizing the use of preclinical information by developing mathematical models to facilitate the transition from […]Read moreMore Tag
Image from left to right: Maarten Doornbos, Leo Price, Bram Herpers, Steven Kunnen.
What is CrownBio´s main focus? Crown Biosciences Netherlands, formerly OcellO, is part of the global contract research organization (CRO) Crown Bioscience. Crown Bioscience is known for its extensive collection of PDX models that are used for in vivo testing. Since 2018 CrownBio also offers in vitro organoid services and upon acquisition of OcellO it is […]Read moreMore Tag
Top: Zofia Bielecka, Barira Islam, Chris Pollard.
Bottom: Hiba Khalidi, Will Redfern, Emily Jo.
What is SIMCYP-Certara’s main focus? Providing in silico solutions to speed-up drug discovery and development: basically, getting safer, more effective drugs to patients faster. By ‘in silico’ we mean data handling, analysis and visualization, modelling & simulation. For example, our tools facilitate and improve decision making in drug discovery, safety and DMPK (drug metabolism and […]Read moreMore Tag
Image from left to right: (Top row) Anthony Lynch, Azmina Mather, Ciaran Fisher, Claire Teague, Crysthiane Ishiy, (Middle row) Daniel Sevin, Deidre Dalmas, Eric Rossman, Jan Roger, Jim Harvey, (Bottom row) Johanna Vappiani, Khuram Chaudhary, Kylie Beattie, Philippa Allen, Valeriu Damian.
How has GSK been involved in the TransQST project? We have actively contributed to each of the organ toxicity work packages (WP5-liver, WP6-kidney, WP7-heart and WP8-gastrointestinal system). Our contribution has included providing legacy datasets, data analysis, modelling, and the generation of novel data (using established and novel technologies) where the need has been identified. All […]Read moreMore Tag
UKHD (Universitätsklinikum Heidelberg)
Bottom image from left to right: Denis Shapiro, Sebastian Lobentanzer, Katharina Zirngibl, Bartosz Bazmanszki, Denes Turei, Rosa Hernansaiz Ballesteros, Martín Garrido Rodríguez-Córdoba, Jovan Tanevski, Ahmet Sureyya Rifaioglu, Attila Gabor, Julio Saez-Rodriguez, Sophia Müller-Dott, Pau Badia i Mompel, Daniel Dimitrov.
What is the main focus of your group? At the Institute for Computational Biomedicine, we develop and apply computational methods to analyse complex biomedical data. Our goal is to acquire a functional understanding of molecular mechanisms in health and disease. We apply these insights to improve diagnosis and to develop novel therapeutics that we apply […]Read moreMore Tag
Top: Meredith E. Crosby, Sean C. Turner, Diana Clausznitzer.
Bottom: Panuwat Trairatphisan, Loic Laplanche, Stacey L. Fossey, Jennifer E. Mollon.
Contributors: Panuwat Trairatphisan Diana Clausznitzer What are your main research interests? In the Quantitative Translational Systems Pharmacology and Toxicology group, we aim to apply quantitative modeling and simulation methods to support the development of new medications and treatment modalities to improve patients’ lives. PK/PD modeling for drug pharmacokinetics and efficacy is routinely and successfully integrated […]Read moreMore Tag
IMIM (Fundació Institut Mar d’Investigacions Mèdiques)
Top: Juan Manuel Ramírez, Josep Saüch, Ferran Sanz, Miguel Angel Mayer, Angela Leis Machin, Lluis Domínguez.
Bottom: Francesco Ronzano, Alexia Giannoula, Judith Perez Granado, Laura I. Furlong, Janet Piñero, Emre Guney.
What is IMIM’s main focus? Our research group Integrative Biomedical Informatics, which belongs to IMIM (Institut Hospital del Mar d’Investigacions Mèdiques) and UPF (University of Pompeu Fabra) located in Barcelona, Spain, is focused on developing bioinformatic tools to gain insight from biomedical data for improving human health. We use data mining and integration and natural […]Read moreMore Tag
ULIV (University of Liverpool)
Top: Chris Goldring, Lucia Livoti, Mark Pritchard, Giusy Russomanno, Rosalind Jenkins.
Bottom: Kevin Park, Carrie Duckworth, Ian Copple, Rowena Sison-Young, Colette Kelly
What is the University of Liverpool’s main focus? Here at the University of Liverpool we contribute to several aspects of TransQST including academic project management, wet laboratory experimentation in the areas of liver and gastrointestinal toxicity (GIT) and data interpretation associated with drug-induced liver injury (DILI). Our main scientific focus is to provide a better […]Read moreMore Tag